Revision as of 23:51, 6 May 2024

Back to Top

Section editor
	Gaurav Goyal, MD UAB Birmingham, AL, USA LinkedIn

1 regimens on this page 1 variants on this page

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

Consensus guidelines

2018: Abla et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease PubMed

NCCN

NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Histiocytic Neoplasms.

All lines of therapy

Cobimetinib monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence
Diamond et al. 2019 (MSK 15-216)	2016-NR	Phase 2, fewer than 20 pts in this arm (RT)

Note: there were N=2 patients with this type of histiocytosis.

Targeted therapy

Cobimetinib (Cotellic) 60 mg PO once per day on days 1 to 21

28-day cycles

References

MSK 15-216: Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02649972

@@ Line 1: / Line 1: @@
-{| class="wikitable" style="text-align:center; width:50%;"
+<span id="BackToTop"></span>
-!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
+<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
-|-
+[[#top|Back to Top]]
-|style="background-color:#F0F0F0"|[[File:Ronaldgo.jpg|frameless|upright=0.3|center]]
+</div>
-|<big>[[User:Ronaldgo|Ronald S. Go, MD]]<br>Mayo Clinic<br>Rochester, MN</big>
+{{#lst:Editorial board transclusions|hist}}
-|-
-|}
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
@@ Line 13: / Line 11: @@
 {{TOC limit|limit=3}}
 =Guidelines=
+'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
 ==Consensus guidelines==
-*'''2018:''' Abla et al. [http://www.bloodjournal.org/content/131/26/2877.long Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease] [https://www.ncbi.nlm.nih.gov/pubmed/29720485 PubMed]
+*'''2018:''' Abla et al. [http://www.bloodjournal.org/content/131/26/2877.long Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease] [https://pubmed.ncbi.nlm.nih.gov/29720485/ PubMed]
+==[https://www.nccn.org NCCN]==
+*''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1502 NCCN Guidelines - Histiocytic Neoplasms].''
 =All lines of therapy=
 ==Cobimetinib monotherapy {{#subobject:a6f6dd|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:#fecb7f|Variant=1}}===
+{| class="wikitable" style="color:white; background-color:#404040"
+|<small>'''FDA-recommended dose'''</small>
 |-
-|[[#top|back to top]]
 |}
-===Regimen {{#subobject:#fecb7f|Variant=1}}===
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-{| class="wikitable" style="width: 50%; text-align:center;"
+!style="width: 33%"|Study
-!style="width: 25%"|Study
+!style="width: 33%"|Dates of enrollment
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438729/ Diamond et al. 2019 (MSK 15-216)]
-|style="background-color:#ffffbe"|Pilot, <20 pts in this arm
+|2016-NR
+|style="background-color:#ffffbe"|Phase 2, fewer than 20 pts in this arm (RT)
 |-
 |}
 ''Note: there were N=2 patients with this type of histiocytosis.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Cobimetinib (Cotellic)]] 60 mg PO once per day on days 1 to 21
 '''28-day cycles'''
+</div></div>
 ===References===
-# '''MSK 15-216:''' Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. [https://www.nature.com/articles/s41586-019-1012-y link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438729/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/30867592 PubMed]
+# '''MSK 15-216:''' Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. [https://doi.org/10.1038/s41586-019-1012-y link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438729/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30867592/ PubMed] [https://clinicaltrials.gov/study/NCT02649972 NCT02649972]
 [[Category:Rosai-Dorfman-Destombes disease regimens]]
 [[Category:Disease-specific pages]]
 [[Category:Histiocytoses]]

Difference between revisions of "Rosai-Dorfman-Destombes disease"